Entrada Therapeutics, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-42.8M | $-39.7M | $-39.2M | $-44.1M | $-43.1M | $-17.3M | $1.1M | $-14.0M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $800.0K | $805.0K | $850.0K | $1.2M | $1.1M | $946.0K | $1.0M | $900.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $5.2M | $4.7M | $4.4M | $5.1M | $5.0M | $5.1M | $4.7M | $4.9M |
| Net Cash from Operating Activities | $-32.5M | $-41.7M | $-32.2M | $-28.3M | $-29.5M | $-38.5M | $-31.6M | $-24.3M |
| Investing Activities | ||||||||
| Capital Expenditures | $11.0K | $44.0K | $-207.0K | $-171.0K | $275.0K | $1.1M | $635.0K | $639.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $54.9M | $27.0M | $29.1M | $49.1M | $33.8M | $4.8M | $53.4M | $-82.9M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $350.0K | $100.0K | $192.0K | $8.0K | $337.0K | $350.0K | $1.4M | $-11.0K |
| Net Change in Cash | $22.8M | $-14.6M | $-2.9M | $20.8M | $4.6M | $-33.4M | $23.2M | $-107.2M |
| Free Cash Flow | $-32.5M | $-41.7M | $-32.0M | $-28.1M | $-29.8M | $-39.7M | $-32.2M | $-24.9M |